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Abstract
The respiratory epithelium is a primary site for the deposition of microorganisms that are acquired
during inspiration. The innate immune system of the respiratory tract eliminates many of these
potentially harmful agents preventing their colonization. Collectins and cationic antimicrobial
peptides are antimicrobial components of the pulmonary innate immune system produced by
respiratory epithelia, which have integral roles in host defense and inflammation in the lung.
Synthesis and secretion of these molecules are regulated by the developmental stage, hormones, as
well as many growth and immunoregulatory factors. The purpose of this review is to discuss
antimicrobial innate immune elements within the respiratory tract of healthy and pneumonic lung
with emphasis on hydrophilic surfactant proteins and β-defensins.
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Introduction
The respiratory epithelium is a mucosal surface that routinely comes in contact with
environmental substances including particulate matter, vapors, aerosols, and microbial
pathogens.32 The innate immune components of the respiratory tract eliminate many of these
potentially harmful substances. These components include coughing, the mucociliary
escalator, phagocytosis by leukocytes such as pulmonary alveolar macrophages and pulmonary
intravascular macrophages,3,91 the complement cascade,66 interferons,50,106 neurokinins,11,
112 and antioxidants.91 More recently, additional components of the mucosal secretions such
as defensin peptides, anionic peptide (AP), and surfactant proteins are increasingly becoming
appreciated for their role in preventing microbial colonization/infection and also for triggering
the adaptive immune response.17,146
Cellular Components of the Respiratory Epithelium
The upper respiratory tract (nasal cavity, sinuses, and trachea) and larger airways of the lower
respiratory tract are lined by pseudostratified, ciliated epithelium and submucosal glands (Fig.
1).32 Other epithelial cells include mucus-secreting goblet cells, small mucous granule cells,
and brush cells.7 The number of basal cells decreases with the decreased diameter of airway
branches, and the epithelium becomes simple cuboidal. At the bronchiolo-alveolar junction,
nonciliated (Clara) cells are abundant. The alveolar epithelium consists of a continuous layer
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of 2 principal cell types, thin, elongate type I pneumocytes (ATI cells), which cover 95% of
the alveolar surface, and cuboidal to rounded type II pneumocytes (ATII cells).80 In addition,
there are also mucous and serous epithelial cells of the tracheal and bronchial submucosal
glands, which together with the pseudostratified epithelium and alveolar epithelial cells serve
as an important physical barrier, and also produce and modify airway surface liquid (ASL).131
Function of the Respiratory Epithelium
Ciliated epithelial cells participate in mucociliary clearance, form a physical barrier, and secrete
a broad spectrum of antimicrobial factors.32,131 Clara cells are the major progenitors of ciliated
cells after bronchiolar injury,28,64 and are involved in the detoxification of xenobiotic
compounds through cytochrome P-450 monooxygenase system activity.91 Clara cells produce
surfactant proteins and Clara cell secretory 10-kd protein (CCSP/CC10), which are natural
regulators of airway inflammation and cytodifferentiation markers.28,107 ATII cells are
responsible for pulmonary surfactant synthesis, storage in lamellar bodies, secretion, and
recycling.80,124 They also act as stem cells by repopulating the lung with ATI and ATII cells
during normal tissue turnover and during the repair of alveolar epithelium after injury.
Recently, it has been shown that the dendritic cell-lysosomal associated membrane protein
(DC-LAMP/CD208) is constitutively expressed by mouse, sheep, and human ATII cells and
can be used as a marker for normal as well as transformed (adenocarcinoma) ATII cells.124
ATII cells also express cathepsins, major histocompatibility complex class II molecules,
intercellular adhesion molecule-1 (CD54), and costimulatory molecules such as CD80 and
CD86.124 For ATI (also known as membranous pneumocytes), one of the most useful
differentiation markers is T1α because it is not expressed by ATII cells or endothelial cells.
145 The main function of ATI cells is to facilitate gaseous exchange. There is limited data on
ATI cells’ metabolic and immune functions; however, these cells may play a role in the
maintenance of normal alveolar homeostasis and protection from injury, lung development and
remodeling, host defense, tumor/growth suppression, surfactant metabolism, and other
activities.30
Airway Surface Liquid
The airway surface liquid represents a first line of defense against inhaled pathogens.94 It
consists of the superficial gel or mucus layer and the layer of periciliary fluid, which are
separated by a thin layer of surfactant (Fig. 1).119 The mucus layer is 93–95% water and 5–
7% solid material principally composed of mucins (large glycoproteins) admixed with
phospholipids, proteoglycans, cellular debris, and various proteins some of which possess
antimicrobial, antiprotease, and antioxidant activity.85 The mucus traps inhaled particles and
microbial pathogens, neutralizes soluble gases, and is cleared by an interaction between airflow
and cilia activity.91 The periciliary fluid layer is a watery layer that surrounds the cilia on the
apical surface of the ciliated cells.94 This layer is necessary for efficient ciliary beating and
mucin hydration. Surfactant is 80% phospholipids (phosphatidylcholine being the most
abundant), 12% neutral lipids (cholesterol being the most abundant), and 8% surfactant proteins
(SP) including hydrophilic SP-A and SP-D, and hydrophobic SP-B and SP-C.108 The primary
function of surfactant is to regulate the surface tension at the air–liquid interface, preventing
alveolar collapse at low lung volumes and overinflation at high lung volumes. Surfactant also
facilitates effective spreading of mucus, preservation of gel and periciliary fluid integrity, and
beating of cilia without entanglement.
Antimicrobial Factors of Airway Surface Liquid
Airway surface liquid contains several proteins and peptides with antimicrobial activity (Table
1).22,32,34,75,123,125,126,131,143,144 Most of these factors act cooperatively in their microbicidal
activity and the degree of their activity depends on the ionic strength of the solution.131 With
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increased ionic strength of the ASL, the antimicrobial activity of ASL components decreases
dramatically.
Lysozyme and lactoferrin are the most abundant proteins in ASL and are present at 0.1–1 mg/
ml concentration.43 Lysozyme was first recognized by Alexander Fleming in 1922. It is a 14-
kd enzyme produced by neutrophils, monocytes, macrophages, and epithelial cells.43,131 It
enzymatically cleaves glycosidic bonds of the bacterial membrane peptidoglycans or kills
bacteria by a nonenzymatic mechanism. Lactoferrin is an 80-kd cationic iron-binding protein
and is also produced by neutrophils and epithelial cells. This protein inhibits growth of iron-
requiring bacteria and can also be directly microbicidal through its N-terminal cationic
fragment.
Antiproteinases are also important constituents of ASL that are involved in the acute phase of
inflammation.104,125 Their molecular characteristics include low-molecular weight, positive
charge, and numerous disulfide bonds. They are present at the mucosal surfaces and protect
against noxious effects of proteolytic enzymes released by phagocytic cells thereby controlling
excessive inflammation and septic shock. An important member of antiproteinases is secretory
leukoprotease inhibitor (SLPI), a low-molecular-weight cationic proteinase inhibitor produced
by epithelial cells and macrophages. This factor acts as an effective inhibitor of neutrophil
elastase via the C-terminal domain. Secretory type II phospholipase A2 (PLA2) is another
antiproteinase that belongs to a growing family of enzymes produced by epithelia and blood-
derived cells. Such enzymes are involved in cytokine-mediated inflammation, surfactant
degradation, and bactericidal activity especially against Gram-positive bacteria.5,47,88 Other
antiproteinases include locally synthesized and secreted elastase-specific inhibitor (elafin), and
systemic antiproteinases produced in the liver and secreted in the circulation such as α1-
antichymotrypsin and α1-proteinase inhibitor.
Antimicrobial peptides and proteins from the ASL that have received the least attention are
those produced by respiratory epithelia, including CC10, APs, cationic antimicrobial peptides
(AMP), and collectins. CC10 protein is induced by corticosteroids and is a potent anti-
inflammatory cytokine produced by Clara cells. Although tumor necrosis factor- (TNF-α)
released during lung inflammation increases the expression of both CC10 and PLA2, CC10
inhibits the activity of PLA2.71,88,152 Additional features of CC10 include a dose-dependent
suppressive effect on TH2 cytokine expression and a potential protective role in lung
tumorigenesis.71,150
Anionic peptides are small, hydrophilic peptides that contain homopolymeric regions (e.g., 5–
7 residues) of aspartic acid, which are responsible for their negative charge.16,41 They have
been detected in the lungs, bronchoalveolar lavage (BAL) fluid, and pulmonary surfactant of
humans, sheep, and cattle. For maximal bactericidal activity, APs require zinc as a cofactor,
which may allow the peptide to overcome the net negative charge once on the microbial surface.
17
Collectins
Collectins produced by vertebrates are a family of proteins that include mannan-binding lectin
(MBL/mannose-binding protein), collectin liver 1 (CL-L1), collectin placenta 1 (CL-P1), SP-
A, SP-D, conglutinin, 43-kd collectin (CL-43), and 46-kd collectin (CL-46), the last three being
found only in the bovidae.57,62,68 These proteins share a common structure made of a C-
terminal located C-type lectin domain, known as a carbohydrate recognition domain (CRD),
which is attached to a collagen-like region via an alpha-helical coiled-coil neck region. To
distinguish between self and non-self, collectins need to recognize and bind complex
glycoconjugates on microorganisms. Collectin binding takes place via the CRD, which
preferentially binds mannose-like ligands such as maltose, which is favored by SP-D, N-acetyl-
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D-glucoseamine, which is favored by conglutinin, and CL-46, or D-mannose, which is favored
by CL-43. This leads directly to agglutination or neutralization of the microorganism. The
binding recruits inflammatory cells and causes opsonization of the microorganisms for
phagocytosis. Although some collectins such as MBL and conglutinin have an important
function in systemic response to microbial challenge, the principal area of interest for this
review include hydrophilic surfactant proteins SP-A and SP-D, also known as lung collectins,
which are a part of more localized response of the lung to injury.27
Lung Collectins
Functional Roles
A large body of evidence has been collected for at least four potential functional roles of lung
surfactant proteins based on in vitro and in vivo studies.29 These roles include antimicrobial,
anti-inflammatory, immunomodulatory, and surfactant regulatory activities.
Lung collectins bind, aggregate, and opsonize different microorganisms including Gram-
positive and Gram-negative bacteria, enveloped (influenza A virus [IAV], respiratory syncytial
virus [RSV]) and nonenveloped viruses (Rotavirus), and fungi to enhance phagocytosis,
killing, and clearance of microorganisms from the lung (Table 2).68 Initially, SP-A and SP-D
have an antimicrobial role that is often followed by a proinflammatory response to destroy the
pathogen and prevent further spread. In vitro, SP-D enhances phagocytosis of RSV by alveolar
macrophages and neutrophils, and suppresses the inhibitory effect of RSV on oxygen radical
production by these cells.82 SP-D also inhibits the infectivity and hemagglutination activity of
IAV in vitro by blocking pathogen-target cell attachment sites.29 Next, SP-D binds,
agglutinates, and/or kills pathogens, resulting in enhanced physical or cellular clearance.25 SP-
D agglutinates Mycobacterium tuberculosis but inhibits its internalization;29 a more recent
study shows that both SP-A and SP-D may enhance mannose receptor-mediated phagocytosis
of Mycobacterium avium by macrophages.79 SP-A can also cause direct killing of
microorganisms by inducing the formation of reactive oxygen species (ROS).53 In addition,
both SP-A and SP-D can inhibit the proliferation of pathogens such as Gram-negative bacteria
by increasing the permeability and disrupting the microbial cell membrane.147
According to in vivo studies, the antimicrobial role of SP-A and SP-D appears to depend on
the type of pathogen and may be species-specific. In wild-type mice, SP-D levels increase
markedly after IAV infection,117 whereas decreased viral clearance is observed after challenge
of SP-A knockout (SP-A –/–) mice with RSV96 or SP-D knockout (SP-D –/–) mice with RSV
and IAV.29,82 In neonatal lambs infected intratracheally with parainfluenza type 3 (PI-3) virus,
SP- A and SP-D mRNA levels are significantly elevated in the lung.51 Regarding bacterial
infection, SP-A –/– mice exhibit delayed microbial clearance of group B streptococcus,
Haemophilus influenzae, and Pseudomonas aeruginosa.96 SP-D –/– mice clear tested bacteria
as efficiently as wild-type mice;57 however, there is increased inflammation and oxidant
production, and reduced macrophage phagocytosis in response to intratracheal instillation of
group B streptococcus and H. influenzae.29 In rats, after the intratracheal inoculation of
lipopolysaccharide (LPS), message levels and BAL fluid contents of both SP-A and SP-D
significantly increase at 24 hours and 72 hours postinoculation, respectively, underscoring the
role of these 2 proteins in the acute phase of lung inflammation.98 In lambs, during the
progression of Mannheimia haemolytica-induced bronchopneumonia into chronicity, the SP-
D protein is reduced to near absence in hyperplastic bronchiolar epithelial cells.52 indicating
that the state of epithelial differentiation may influence the SP-D expression. Our recent studies
indicate that elevated levels of SP-A and SP-D (as well as sheep β-defensin-1) mRNA in the
lungs of neonatal lambs infected with PI-3 virus are associated with simultaneous decrease in
PI-3 virus replication.51 These findings may suggest that lung collectins (and defensins) are
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synthesized to bind to PI-3 virus, as collectins bind to other viruses, and to neutralize it directly
or indirectly.
The second role of lung surfactant proteins is anti-inflammatory. This role can be explored by
using SP-A –/– and SP-D –/– mice. The phenotypic features of SP-D –/– mice include chronic
low-grade pulmonary inflammation, ATII cell hyperplasia with giant lamellar bodies, excess
alveolar surfactant phospholipid, and emphysematous changes with dilated airspaces and
pulmonary fibrosis.25 The inflammation is characterized by peribronchial monocytic infiltrate
with an excessive number of alveolar macrophages that produce increased amounts of ROS
and matrix metalloproteinases (MMP). Inflammation in this model can be explained by
increased lung expression of monocyte chemoattractant protein-1 (MCP-1) mRNA, which can
be corrected by the treatment of SP-D –/– mice with recombinant SP-D.25 Another mechanism
of lung inflammation would be increased numbers of apoptotic macrophages present in SP-D
–/– mice, because failure in clearing apoptotic cells can lead to triggering of inflammation.25
SP-A –/– mice do not show detectable abnormalities in histology, lung wet weight, lung
volume, compliance, or surfactant lipid metabolism, but clearly demonstrate increased
susceptibility to infection by respiratory pathogens, enhanced lung inflammation, and
increased incidence of splenic dissemination after intratracheal instillation of bacteria.53,62 In
addition, surfactant isolated from these mice lacks tubular myelin, but surprisingly these mice
have normal postnatal survival with no detectable alteration in pulmonary function.62
SP-D is capable of regulating an inflammatory response to microorganisms and microbial
products.29 After bacterial challenge, SP-D inhibits pulmonary secretion of the
proinflammatory cytokines such as IL-1, IL-6, and TNF-α.57 SP-A –/– mice show increased
production of TNF-α and nitric oxide (NO) upon intratracheal challenge with P. aeruginosa or
LPS.53 In addition, peptidoglycanand zymosan-induced secretion of TNF-α can be inhibited
by direct interaction of SP-A with Toll-like receptor (TLR)-2 on macrophages.79
The third role of lung collectins is immunomodulation. SP-D mediates inhibition of IL-2
secretion by monocytes, and leads to reduced T-lymphocyte proliferation.57 It can bind to
oligosaccharides associated with dust mite allergens and inhibit the binding of specific IgE
molecules to those allergens.29 Glycosylation of viral coat proteins such as those of IAV, an
adaptation that is believed to help viruses evade antibody-mediated neutralization, is associated
with enhanced reactivity of SP-D.117 SP-A can also inhibit proliferation of stimulated
lymphocytes and affect IL-2 production.53 Other functions revealed by in vitro studies include
chemotaxis of alveolar macrophages, neutrophils, and monocytes, antioxidant properties, and
altered macrophage production of MMPs.25 One study even suggests that exogenous SP-A can
significantly protect lung from injury induced by ischemia-reperfusion of isolated rat lungs by
reducing the SP-A loss and by activating the upregulation of endogenous NO synthetase
(eNOS).99
The fourth role, which was the first discovered functional role of lung surfactant proteins, is
nonimmunologic and is related to the function of surfactant.96 SP-A is more important than
SP-D in this regard, and has been reported to regulate surfactant homeostasis by controlling
the secretion and uptake of surfactant by ATII cells, to protect the surface activity properties
of surfactant from functional inhibitors, to inhibit phospholipase A1, and to be required for the
formation of tubular myelin. In addition, it has been suggested that an appropriate SP-A level
in fetal lung may determine the time of labor.26 According to this theory, when SP-A reaches
a yet undefined critical threshold in the ASL of fetal lung, it stimulates macrophages via TLRs
causing proinflammatory cytokine release and macrophage migration to the uterus, which in
turn leads to increased uterine contractility and parturition.
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Modulation of SP-A and SP-D function
Certain ligands and inflammatory products can serve as competing ligands for collectins that
reduce their activity, or can cause their partial cleavage or complete degradation.29,65,120
Glucose concentrations encountered in diabetes mellitus can interfere with the ability of SP-
D to interact with specific strains of IAV in vitro and cause increased susceptibility of mice to
certain influenza viruses in vivo.115 Both SP-A and SP-D bind free DNA and the DNA present
on apoptotic cells via their CRD's and collagen-like domains, although SP-D binds nucleic
acids more effectively at physiological salt conditions.111 This feature may allow lung
collectins to play a role in decreasing the inflammation caused by DNA in lung, which at the
same time may inhibit lung collectin carbohydrate binding ability. Interaction of SP-A with
other proteins such as fibrinogen can induce inactivation of SP-A.54 Phosphatidylinositol (PhI)
from surfactant may serve as a ligand for SP-D and suppress interaction between SP-D and
microorganisms in diseases in which PhI levels are elevated such as in acute respiratory distress
syndrome (ARDS).105 Furthermore, neutrophil serine proteases including cathepsin G,
elastase, and proteinase-3 contribute to degradation of SP-A; this may be the reason for low
levels of SP-A in patients with cystic fibrosis.120 These proteases also cleave highly conserved
CRD subregions of SP-D markedly reducing the ability of SP-D to promote bacterial
aggregation and binding to yeast mannan in vitro.65 In addition, bacterial products such as P.
aeruginosa elastase, a zinc-metalloprotease, also cause formation of nonfunctional SP-D
degradation products4,146 Finally, it has been shown that the function of SP-A depends on
cation concentration, especially calcium, in the environment, which affects the quaternary
organization of the SP-A protein.118
Regulation of SP-A and SP-D expression
Synthesis and secretion of surfactant components are developmentally regulated. Surfactant
starts to be synthesized in progressively increasing amounts during the last stage of lung
development, the alveolar stage.77,100 In humans, SP-A is not detectable in fetal lung until the
30th week, whereas SP-D is first detected in the second trimester of gestation (40 weeks being
the full term).35,77,108 In sheep, mRNA content of SP-A is low to nondetectable at 99–100
days of gestation (145–150 days being the full term), and it progressively increases starting at
about 120 days of gestation to term and into the postnatal period.100,139 Because pre- and full-
term infants and animals lack fully effective adaptive immune response and the maternal
immunoglobulin levels can vary from very high to low or absent,37 regulated expression of
surfactant is especially important in this age group that largely depends on its innate immune
response.
In addition to being dependent on the developmental stage of lung maturation, lung surfactant
proteins are also regulated by hormones, growth factors, and other regulatory substances (Table
3).44 In Table 3, discrepancies in the effect of different factors on SP-A and SP-D expression
can be observed, suggesting that these 2 proteins are not coordinately regulated.35
Tissue distribution
SP-A and SP-D are synthesized by ATII and Clara cells.28 Alveolar macrophages show strong
cytoplasmic and/or membrane labeling with antibody against SP-D; however, because
macrophages express no detectable SP-D mRNA, it is likely that intracellular SP-D protein is
caused by phagocytosis in conjunction with surfactant metabolism.29 The lamellar bodies of
ATII cells serve as storage organelles for surfactant phospholipids and the content of these
organelles is rapidly associated with SP-A upon its secretion into the liquid lining alveoli
(hypophase), which leads to formation of tubular myelin.62,108 Regulated exocytosis of the
lamellar body content involves about 10% of the intracellular surfactant pool per hour, but the
availability of SP-A that is free to interact with ATII cell receptors in the intact lung is unknown.
62 The secretory granules of Clara cells, on the other hand, are primarily responsible for storing
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SP-D and it seems likely that SP-D secretion is regulated via granule exocytosis at this level
of the respiratory tract.29 Although both SP-A and SP-D are expressed in highest amounts in
the distal lung, expression at various extrapulmonary sites has been reported and it appears to
be species specific.62,87 The extrapulmonary sites of SP-A expression include porcine
eustachian tube epithelium,110 rabbit sinus and middle ear mucosa,38 human small and large
intestine,86 vaginal mucosa,92 trachea, thymus, pancreas, and prostate.93 The extrapulmonary
sites for SP-D include porcine eustachian tube epithelium,110 human salivary gland, kidney,
heart, small intestine, prostate gland, and pancreas, rat gastric mucosa, and many other sites.
62
Protein structure
Pulmonary collectins are organized as oligomers assembled from multiple copies of a single
polypeptide chain consisting of 4 structural domains.27,62 The first domain is a short amino-
terminal disulfide-rich domain of 7 (SP-A) to 25 (SP-D) amino acids which is involved in the
interchain interactions. The second domain is a collagen-like domain that forms an extended
fibrillar triple helix 20 (SP-A) to 46 (SP-D) nm long. The third domain forms a short trimeric
coiled-coil domain, and links the collagen-like sequence to the fourth domain, globular CRD.
SP-A is the most abundant surfactant protein in the lung (5.3% of total surfactant weight) and
its monomer measures 28–36 kd.53,63 This protein is usually assembled into octadecamers that
consist of 6 trimeric subunits that form a “bunch-of-tulips” shape.27,63 SP-D is predominantly
assembled as dodecamers that contain 4 homotrimeric subunits arranged in a cruciform shape.
Each SP-D monomer weighs 43 kd.
Receptors
The best characterized host defense receptor for SP-A is a 210-kd cell surface protein (SP-
R210) present on rat ATII cells and alveolar macrophages.68,69 The interaction of SP-A and
SP-R210 occurs through the collagen-like domain of SP-A, and leads to binding of SP-A to
ATII cells and alveolar macrophages, SP-A-mediated uptake and killing of Mycobacterium
bovis, and inhibition of phospholipid secretion.68,96 Both SP-A and SP-D bind to glycoprotein
gp-340, a member of the macrophage scavenger receptor cysteine-rich protein family that has
both soluble and alveolar macrophage membrane-bound components.96 The interaction of lung
collectins with gp-340 leads to binding and aggregation of some bacteria, such as Streptococcus
mutans.113 SP-A also binds to TLR2 resulting in reduced TLR2 binding to peptidoglycans.
87 Other proposed receptors for collectins include cC1qR (calreticulin), CD14, and 30-kd
alveolar cell membrane protein.57,63
Lung collectin genes
In humans and nonhuman primates, SP-A is encoded by 2 genes, SP-A1 and SP-A2, with
several alleles at each locus.76,83 In other species such as rabbits, rats, mice, and dogs SP-A is
encoded by a single-copy gene.83 Human SP-D is encoded by a single gene, which has also
been confirmed in rodents and ruminants.27,48 Both human SP-A and SP-D genes are found
on the long arm of chromosome 10 at q22.2–23.1 region, near the MBL gene.27 Bovine SP-D
gene is found at the same locus as the conglutinin gene on Bos taurus chromosome 28 (BTA
28) at position q1.8, and comprises 9 exons spanning approximately 10.5 kb.49 The bovine
gene encoding SP-A is located proximal to the bovine SP-D gene at BTA 28 at position q1.8–
1.9.48 The order of bovine genes for SP-A, MBL-A, and SP-D is homologous with the order
of the analogous genes found in humans and mice. Regulation of lung surfactant protein gene
expression is multifactorial and controlled by transcriptional and/or post-transcriptional
(mRNA stability) mechanisms.14 The function of surfactant protein promoter depends on the
combined activity of many transcription factors, one of them being thyroid transcription factor
1 (TTF-1/Nkx2.1), a common positive regulator of surfactant protein promoter activity.14
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Cationic Antimicrobial Peptides
Two major families of cationic AMP are defensins and cathelicidins.78 Defensins can be further
divided into 3 classes, α-, β-, and θ-defensins based on pairing of their 6 cysteine residues in
the disulfide bridges.32,140,149 Human α-defensins are 29–35 amino acids in length and contain
3 disulfide bridges in a 1–6, 2–4, 3–5 arrangement.78 These peptides were first described in
human tissues and include 6 members.140 Four members, named human neutrophil peptides
(HNPs) 1–4, have been found in the azurophilic granules of neutrophils. The other 2, human
defensin (HD)-5 and HD-6, are located in secretory granules of intestinal Paneth's cells and in
female genital epithelial cells. In the early 1990s, β-defensins were identified.155 β-defensins
are 36–42 amino acids in length and have 3 disulfide bridges arranged in a 1–5, 2–4, 3–6 pattern.
78 More than 28 human β-defensins have been identified7 among which the best studied include
human β-defensin (HBD)-1 expressed in the epithelial cells of respiratory tract including lung
and trachea, pancreas, kidney, gastrointestinal epithelium,72,97 urogenital tract,157 and
reproductive tract;84 HBD-2 expressed in skin, trachea, and lung;130 and HBD-3 expressed
predominantly in the skin but is also expressed in the respiratory tract.74 In mice, over 40 β-
defensins have been identified including mouse β-defensin (MBD)-1, -2, -3, and -4.7 MBD-1
is homologous to HBD-1 at the gene level, and is found in multiple epithelia with highest levels
in kidney,8 whereas MBD-3 exhibits homology at the gene level to HBD-2, and is detected in
lung, salivary gland, and reproductive organs.8 Bovine β-defensin family members include
neutrophil defensins (BNBD) 1–13 that are expressed in bovine neutrophils and macrophages;
tracheal antimicrobial peptide (TAP) expressed in nasal epithelium, trachea, bronchioles, and
alveolar macrophages; and lingual antimicrobial peptide (LAP) expressed in the epithelial cells
of tongue and alveolar macrophages.17,43 Two ovine β-defensins have been described, sheep
β-defensin (SBD)-1 and -2. SBD-1 expression has been detected from the tongue to colon with
the exception of distal ileum where SBD-2 predominates.72,101 SBD-1 is also expressed in the
trachea,72 whereas both SBD-1 and SBD-2 are expressed in the lung.2,51
Cathelicidins, another important family of cationic AMP, have been found in cows, pigs, sheep,
goats, horses, mice, guinea pigs, rabbits, and humans.17,132 Their main structural feature is a
high-level sequence identity in the 5′ region, named the N-terminal cathelin domain because
it is also found in cathelin, a cysteine protease inhibitor. The C-terminal domain of cathelicidins
provides them with antimicrobial activity. In most species, cathelicidins are expressed in
myeloid precursor cells. Other cells and tissues known to express cathelicidins include mature
peripheral porcine neutrophils, human airway epithelium, and the testis.9,114 Some examples
of cathelicidins include bovine myeloid antimicrobial peptide (BMAP)-34, BMAP28, Bac5,
Bac7 in bovine; OaBac11, sheep myeloid antimicrobial peptide (SMAP)-29, SMAP34 in
sheep; porcine myeloid antimicrobial peptide (PMAP)-23, cecropin P1, PR-39, protegrin-1 in
pigs; equine cathelicidins eCATH-1, -2, and -3 in horses; and LL-37 (also known as hCAP-18)
in humans.17,154
Functional roles
Cationic AMPs have multiple roles and the best-studied ones are included in Table 4. These
peptides have the potential to kill or neutralize bacteria (Gram-positive and Gram-negative),
fungi (including yeasts), viruses (even enveloped, like human immunodeficiency virus [HIV]),
and parasites (including planaria, nematodes, trypanosomes, and plasmodia).132 The peptides
are selective in that normal host cells are relatively resistant to their action. This is based on a
few important differences between cytoplasmic membranes of prokaryotic and eukaryotic
cells.95 The most striking difference is the composition and topological arrangement of lipids.
The outer surface of mammalian cell membranes is composed of electrically neutral
(zwitterionic phospholipids), mainly phosphatidylcholine (PC) and sphingomyelin. Bacterial
membranes, on the other hand, contain large amounts of negatively charged phospholipids,
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phosphatidylglycerole (PG) and cardiolipin (CL). In addition, the outer membranes of Gram-
negative bacteria are covered with polyanionic LPS. Therefore, cationic peptides prefer binding
to bacteria because of electrostatic interactions between positive charges of the peptides and
negative charges of the lipids. The second important difference is that unlike eukaryotic cell
membranes, prokaryotic cell membranes lack cholesterol, which also contributes to
prokaryotic cells being a better target. The last striking differentiating factor of prokaryotic
cells is that they possess a large transmembrane potential of –140 mV, compared to the low
membrane potential of eukaryotic cells (15 mV). Unfortunately, there are some exceptions to
these rules and certain cationic AMP peptides, like melittin from bees, mastoparan from wasps,
or charybdotoxin from scorpions, are potent toxins.132
Given the diversity of AMP and of target microorganisms, it is likely that there is not one
unique mechanism for their mode of action.39 The only constant is that these peptides do not
need a metabolically active cell to exert their effect. Based on studies done with magainins,
cationic AMP isolated from frog skin, a general mechanism of action on Gram-negative (2-
cell membrane) bacteria has been proposed.95 It includes 2 steps, with a note that the second
step could also be applied to Gram-positive (1-cell membrane) bacteria. In the first step,
positively charged AMP interacts with polyanionic LPS at sites of LPS where divalent cations
usually bind to cross bridge adjacent LPS molecules and stabilize the outer membrane. The
competitive displacement of these divalent cations (Ca2+, Mg2+) by the bulkier peptides leads
to lesions in the outer bacterial membrane visualized as surface blebbing. This model has been
described by Robert Hancock, and is called “self-promoted uptake.”56 In the second step, AMP
associates with the negatively charged phospholipid membrane and form holes (“aggregate
channels”) in the membrane when certain, critical AMP concentrations have been reached.
Examples of peptides that cause formation of membrane channels are cecropins and defensins.
17 Other cationic AMP like Bac5 and Bac7 alter transport and energy metabolism in the
cytoplasmic membrane of pathogens. Once the peptides are within the cells, they can bind to
cytoplasmic polyanions such as DNA and interfere with DNA/protein synthesis (e.g., PR-39),
and then stimulate autolytic enzymes.17,39 It has also been demonstrated that AMP can
inactivate bacterial heat-shock proteins (DnaK) without binding to human analogous heat
shock protein Hsp70 and affecting its normal function.109 The mechanism of antiviral action
is less understood, but studies show that β-defensins can cause disruption of the viral envelope,
whereas α-defensins may also interfere with intracellular cell signaling inhibiting viral
replication.23,102
Modulation of AMP function
In vitro experiments have shown that defensins are microbicidal at μM concentrations against
many Gram-positive and Gram-negative bacteria, yeast, fungi, and some enveloped viruses if
there is low-salt concentration (e.g., 10 mM sodium phosphate) in the environment.43 As the
salt concentration increases, the activity of lung innate antibacterial factors such as HBD-1 and
-2, as well as lactoferrin, lysozyme, histatin, and cathelicidin can be completely inhibited,
which likely occurs in the lungs of patients with cystic fibrosis.127 Using the osmolyte xylitol
to reduce airway surface liquid salt concentration,153 and/or exogenously introducing cationic
AMP that are not salt-sensitive (e.g., sheep cathelicidin SMAP29) are showing promising
results in enhancing AMP activity.134 Another factor influencing AMP activity is pH, which
can affect the electrical charge of peptides.136 This may lead to changes in peptide
conformation and activity. The ability of some peptides to be active at low pH conditions can
be used for drug generation, because this feature would allow the peptides to act in
phagolysosomes. Furthermore, because of their cationic properties, cationic AMP easily forms
complexes with various serum proteins like serum albumin and α2-macroglobulin, or bacterial
degradation products of extracellular matrix, which may abolish their activity.1,70
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Regulation of expression
All cationic AMPs can have constitutive (normally present in animals) and/or inducible (upon
stimulation) expression.78 Two examples of peptides with constitutive properties are HBD-1
and MBD-1. The expression of inducible peptides can be stimulated during infection or
inflammation with LPS, lipoteichoic acid (LTA), TNF, IL-1β, IFN-γ, and other mediators of
inflammation.55,58 These AMP include human HBD-2, -3, -4, and LL-37,74,78,89 bovine LAP
and TAP,33,121 mouse MBD-2 and -3,78 and others. In addition, like with collectins, the
expression of pulmonary defensins seems to be developmentally regulated in late gestation and
through the neonatal period,101 which leaves a window of immature peptide expression in the
infant that may provide an environment with increased susceptibility to respiratory tract
infection.
The mechanism of AMP gene induction is poorly understood. One of the proposed induction
pathways is LPS-mediated upregulation of AMP genes, which has been directly shown for the
TAP gene in bovine and HBD-2 gene in human airway epithelial cells.133 Cationic AMP also
bind LTA, although with a lower affinity compared to LPS, leading in some cases to production
of TNF-α and IL-6 by murine macrophages.132 In addition, recent studies indicate that retinoic
acid (RA) may have an important effect on AMP gene expression.59 In porcine bone marrow
cells, RA induced expression of cathelicidin PR-39; however, in human keratinocytes,
induction of HBD-2, -3, and -4 mediated by high Ca2+ concentration, proinflammatory
cytokines, phorbol myristate acetate (PMA), and bacteria, was abolished when keratinocytes
were preincubated with RA. The biological effect of RA is achieved by its binding to and
activation of the nuclear retinoic acid receptors (RAR) that belongs to the steroid/thyroid
receptor family.42,59 RAR, in turn, form heterodimers with the retinoid × receptors, which is
followed by its direct binding to specific cis-acting retinoic acid response elements or by its
antagonistic effect on AP-1 (c-Jun/c-Fos)-mediated gene expression. Because the promoter
regions of all inducible HBD genes contain putative binding sites for AP-1, it is possible that
AP-1 plays an important role in the signal transduction during induction and downregulation
of defensin gene expression.59
Peptide characteristics
Cationic AMP are 12–50 amino acids in length, and have a net positive charge (+2 to +7) owing
to an excess of basic amino acids (arginine, lysine, and histidine).55 Different AMP are needed
to deal with different microorganisms and because of this, single animal species can have more
than 24 different AMPs.17 AMPs fall into 4 principal categories based on their size,
conformational structure, or predominant amino acid structure.17,78 These comprise group I:
linear, α-helical peptides without cysteines (e.g., SMAP and porcine cecropin P1); group II:
β-sheet structures stabilized by 2–3 disulfide bridges (e.g., α- and β-defensins, rhesus theta
defensin-1, and protegrins); group III: linear peptides rich in 1 or more amino acids (e.g., PR-39,
Bac5, Bac7, indolicidin, and prophenin); and group IV: peptides with loop structures (e.g.,
bactenecin and ranalexin). In general, cationic AMPs with best antimicrobial activity are
molecules that have the charged and hydrophilic portions separated from the hydrophobic
areas. This means that either amphipathic or cationic double-wing structures with a
hydrophobic core separating 2 charged segments are preferred, which is determined by their
tertiary structure.132 There is also a group of cationic AMP, which are formed by proteolytic
digestion of larger peptides, such as lactoferricins that are derived from lactoferrin.15
Cationic AMP genes
AMPs of vertebrates are ribosomally synthesized, gene-encoded peptides, meaning that 1 gene
codes for 1 peptide.78 In humans, mice, and rats, both α- and β-defensins colocalize on the
chromosome region that is on human chromosome 8p21–23, mouse chromosome 8, and rat
chromosome 16.55,90,131 In sheep, β-defensin genes that comprise two exons (e.g. SBD-1 and
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-2) have been mapped to sheep chromosome 26, whereas the 4-exon cathelicidin genes have
been mapped to sheep chromosome 19, suggesting homology between human, sheep, cattle,
and mouse AMP gene families.73 AMP genes have intron–exon structure with regulatory
elements in their promoter regions. The primary translational product of exons is a
prepropeptide, which consists of an N-terminal signal sequence for targeting of the
endoplasmic reticulum, a pro segment for correct folding of the mature peptide, intracellular
trafficking, and/or inhibition of activity of the mature peptide, and a C-terminal cationic peptide
that has antimicrobial activity after cleavage.78,81 Cleavage of the propeptide occurs during
later stages of intracellular processing or after secretion. AMP can be stored in cells as
propeptides or as mature C-terminal peptides.
Conclusions
A significant amount of evidence from both in vitro and in vivo studies suggests that SP-A and
SP-D serve numerous functions in innate immune processes. The use of recombinant lung
surfactant proteins in the treatment of diseases such as respiratory distress syndrome in
neonates, emphysema and chronic obstructive pulmonary disease, cystic fibrosis, and asthma
has already shown promising results.24,25 Development of collectin-based therapies for various
pulmonary diseases warrants further investigation.
With increasing development of antibiotic resistance, there is a need to develop new classes
of antibiotics. Cationic AMPs have many of the desirable features of such substances, which
include a broad spectrum activity, rapid killing of bacteria, activity against classic antibiotic-
resistant variants, synergy with antibiotics, neutralization of endotoxins, and activity in vivo.
132 However, despite all these positive features, there are still many issues that need to be
addressed in order for these molecules to be used as systemic therapeutic agents. These include
production costs as a result of their high molecular weight, potential toxicity, and peptide
liability to proteases in the body.55
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Fig. 1.
Schematic presentation of the respiratory epithelium and its production of antimicrobial
peptides and proteins.
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Table 1
Antimicrobial factors or substances in airway surface liquid.
Factors Cell and Tissue Distribution in Lung
Lysozyme34,43,131 Epithelia—serous cells of tracheobronchial submucosal
glands, tracheal and bronchial surface epithelium; neutrophils;
alveolar macrophages; monocytes
Lactoferrin34,43 Epithelia—serous cells of tracheobronchial submucosal
glands, tracheal surface epithelium; neutrophils
Secretory leukoprotease inhibitor43,104,125 Epithelia—serous cells of respiratory submucosal glands and
Clara cells (in vivo); monocytes, alveolar macrophages,
neutrophils, and tracheal, bronchial, bronchiolar, and ATII
cells (in vitro)
Elafin104,125 Epithelia—tracheal, Clara and ATII cells; alveolar
macrophages
Phospholipase A25,47,88 Epithelia; neutrophils
Bactericidal/permeability-increasing protein22 Neutrophils
IgA secretory component36 Epithelia
Surfactant proteins SP-A and SP-D27,28,52,62,87,96 Epithelia—ATII and Clara cells
Anionic peptides17,18,40,41 Epithelia—trachea, bronchioles, alveoli
α- and β- Defensins17,32,43,97,131 Neutrophils; epithelia—conducting airways (and alveoli?)
θ-Defensins142 Neutrophils
Cathelicidins9,17,154 Neutrophils; epithelia—conducting airways, serous and
mucous cells of respiratory submucosal glands
Peroxidases32 Neutrophils; epithelia
Clara cell secretory 10-kd protein (CC10)71,107,150,152 Clara cells
Nitric oxide32 Endothelial cells, macrophages
Uric acid32 Epithelia—respiratory submucosal glands
Aminopeptidase75 Neutrophils; alveolar macrophages; epithelia—bronchial and
alveolar
Proline-rich proteins*123 Epithelia—bronchus
Statherin*123 Epithelia—serous cells of respiratory submucosal glands
Cystatin*123 Epithelia—bronchus
Plunc13,143 Epithelia—trachea and bronchus
*
Note: These proteins have highest production levels in salivary glands. SP-A = surfactant protein A; SP-D = surfactant protein D.
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Table 2
Interaction of surfactant protein A (SP-A) and surfactant protein D (SP-D) with pathogens.
SP-A SP-D
Bacteria Dimannose repeating unit associated with capsular polysaccharides of
some capsular serotypes27
Rough LPS29
LTA and peptidoglycan of Gram-positive bacteria68
Rough LPS
Outer membrane protein of Haemophilus influenzae type A
Lipid component of the cell membrane of Mycoplasma
pneumoniae68
Mycobacterium tuberculosis68
Lipid A domain of Escherichia coli
Gram-positive bacteria68
Mycobacterium tuberculosis68
Enhances mannose receptor-mediated phagocytosis of
Mycobacterium avium by macrophages79
Enhances mannose receptor-mediated phagocytosis of Mycobacterium
avium by macrophages79
Viruses Inhibits influenza virus hemagglutination and infectivity; neutralizes
influenza A virus (IAV) by directly occupying and likely blocking the
coat hemagglutinin (HA) cell attachment site60,61
Inhibits influenza virus hemagglutination and infectivity; binds high-
mannose oligosaccharides present on HA of IAV60,61
Binds to G and F proteins of RSV82
Binds to F proteins of respiratory syncytial virus (RSV)45,128 Hemagglutination inhibition and neutralization of bovine
rotavirus116
Fungi Binds glycoprotein gpA of cyst and trophozoite forms of Pneumocystic
carinii, which enhances binding of organism to alveolar
macrophages27,68
Binds glycoprotein gpA of cyst and trophozoite forms of
Pneumocystic carinii, which enhances binding of organism to
alveolar macrophages27,68
Binds to uncapsulated forms of Cryptococcus neoformans Binds to uncapsulated forms of Cryptococcus neoformans leading to
agglutination
Binds to conidia and specific cell wall glycoproteins of Aspergillus
fumigatus
Binds to conidia and specific cell wall glycoproteins of Aspergillus
fumigatus
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Table 3
Regulation of SP-A and SP-D expression by hormones, growth factors, and other regulatory substances.
SP-A SP-D
Insulin Decreases SP-A (and SP-B) mRNA in human fetal lung explants (HFLE);
may account for increased incidence of respiratory distress syndrome in
infants of diabetic mothers31
Glucose Ligand for SP-D; may account for
increased susceptibility of diabetic mice
to Influenza virus infection115
Glucocorticoids Biphasic response in HFL—increases SP-A mRNA at low concentration and
with short exposure, but decreases with higher concentration;35 in immature
lambs, increases SP-A protein6,139
Increases SP-D mRNA in HFL122
Vascular endothelial growth factor Increases SP-A protein and mRNA in HFLE; possible autocrine and
paracrine regulatory role in pulmonary epithelial cell growth and
differentiation20
Keratinocyte growth factor Increases SP-A mRNA in adult rat lung151 Increases SP-D mRNA in adult rat
lung151
Transforming growth factor β1 Reduces SP-A mRNA in HFLE and arrests lung morphogenesis in
pseudoglandular stage of development;156 potential role of TGF-β1 in
pathogenesis of bronchopulmonary dysplasia12
cAMP, IFN-γ Increase SP-A mRNA in HFLE35
Lipoteichoic acid, tumor necrosis
factor-α, phorbol myristate acetate Decrease SP-A mRNA in HFLE
35,103
IL-4 Increases SP-D in rat ATII cells; may
provide a link between innate and
adaptive immunity during allergic
inflammation21
85–95% O2 Increases SP-A in rat lung98 Increases SP-D in rat lung29
Nitric oxide Increases SP-A protein and mRNA in lamb lung138
Retinoic acid Increases SP-D mRNA in ovine ATII
cells (unpublished data, Grubor B,
Ackermann MR)
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Table 4
Multifunctional roles of cationic antimicrobial peptides (AMP).
Activities Examples
1. Antimicrobial Minimal inhibitory concentration of synthesized peptides used in vitro experiments is 2–16 μM17
Addition of pig protegrin-1 to methicilin resistant Staphylococcus aureus infected mice improved survival from 0 to 100%
137
Decreased production of antifungal peptide drosomycin in knockout Drosophila made animals more susceptible to
Aspergillus fumigatus129
Over-expression of human LL-37 in mouse airways improved survival from 10 to 75% in Escherichia coli infected
animals10
2. Synergistic action Act in synergy with other AMP, host molecules (e.g., lactoferrin, lysozyme), or conventional antibiotics46,56,135
3. Anti-inflammatory α-defensins regulate complement activation and secretion of protease inhibitors67,141
Indolicidin and to a lesser extent bactenecin show selective cytotoxicity to T lymphocytes132
PR-39 peptide inhibits leukocyte (particularly neutrophil) recruitment into inflamed tissue and attenuate myocardial
reperfusion injury in a murine model67
Defensins can inhibit serine protease (e.g., elastase)132
Defensins can inhibit fibrinolysis43
Cationic AMP can downregulate neutrophils’ ability to generate superoxide (by affecting NADPH oxidase)
4. Proinflammatory α-defensins stimulate production of IL-8140
HBD-1 and -2 are chemotactic for immature dendritic cells and memory T lymphocytes1
HBD-6 causes neutrophil recruitment and mild aggravation of concurrent PI-3 virus infection in lambs102
CAP-11, magainin-2, and HBD-2 can stimulate activation and degranulation of mast cells131,140
5. Wound healing Promotion of re-epithelialization of damaged surfaces55
6. Increased bacterial
colonization
Observed in patients with chronic obstructive pulmonary disease; possibly, defensins stimulate adherence of Haemophilus
influenzae to expose it to high concentrations of epithelial-cell derived AMP140
7. Inhibition of
adrenocorticotroph hormone
(ACTH)-stimulated cortisol
production43
8. Bridge between innate and
adaptive immune system
Recruitment of immature dendritic cells and memory T lymphocytes likely through interaction with chemokine receptor
CCR6148
Mice challenged with ovoalbumin antigen produce higher levels of antigen-specific serum IgG when treated with HNP-1
and HBD-219
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